• About the Journal
    Exploration of Targeted Anti-tumor Therapy, a peer-reviewed, open access online journal, publishes articles on all aspects of cancer research, including clinical diagnosis and analysis, case report, prevention, intervention treatment, pre-clinical and clinical trials of all types of cancers. Submissions with good originality, well-designed experiments and rigorous data are particularly welcomed.
    From the Editors-in-Chief
    It is a particularly exciting time to be involved in cancer research and I am delighted to take on the role of co-Editor-in-Chief of the new journal Exploration of Targeted Anti-tumor Therapy. The journal will provide a platform for publication of studies on all aspects of the development of targeted anti-cancer drugs and will appeal to a broad range of readers. I look forward to receiving submissions of your manuscripts describing cutting-edge research in this fast moving and important field.
    Graham Packham
    Co-Editor-in-Chief of Exploration of Targeted Anti-tumor Therapy
    I am really honored to take on the role of co-Editor-in-Chief of this new journal—Exploration of Targeted Anti-tumor Therapy. Like many colleagues, I spent a large part of my professional life researching new cancer therapies. The efforts of the scientific community have allowed the development of targeted therapies to affect significantly the course of the main tumors. In this scenario, ETAT wants to represent a platform for discussion and evaluation on all aspects related to the development of targeted therapies, from the identification of the target to its validation and clinical exploration, including the evaluation of biomarkers of activity and toxicity. We therefore await your contributions to build together a place of confrontation that favors scientific progress in the field of target therapies.
    Nicola Normanno
    Co-Editor-in-Chief of Exploration of Targeted Anti-tumor Therapy
    Latest Articles
    Open Access
    Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors
    Chronic lymphocytic leukemia is a common form of leukemia and is dependent on growth-promoting signaling via the B-cell receptor. The Bruton tyrosine kinase (BTK) is an important mediator of B-cell ...
    Rachael Arthur ... Graham Packham
    Online First: May 22, 2020 Explor Target Antitumor Ther. 2020;1:Online First
    DOI: https://doi.org/10.37349/etat.2020.00009
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    Open Access
    Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer
    Several preclinical studies suggested a potential benefit from combined treatment with inhibitors of epidermal growth factor receptor (EGFR) and angiogenesis, both effective in patients with advance...
    Giuliano Palumbo ... Alessandro Morabito
    Published: April 28, 2020 Explor Target Antitumor Ther. 2020;1:117-132
    DOI: https://doi.org/10.37349/etat.2020.00008
    Open Access
    Case Report
    Multiple adverse drug reactions during all-trans retinoic acid treatment for acute promyelocytic leukemia: differentiation syndrome, bradycardia, intestinal necrosis
    All-trans retinoic acid (ATRA) induces complete remission in a high proportion of acute promyelocytic leukemia (APL). Nevertheless it is be associated with adverse drug reactions that might be life-...
    Valeria Ferla ... Nicola Stefano Fracchiolla
    Published: April 28, 2020 Explor Target Antitumor Ther. 2020;1:109-116
    DOI: https://doi.org/10.37349/etat.2020.00007
    Open Access
    The impact of tumour pH on cancer progression: strategies for clinical intervention
    Dysregulation of cellular pH is frequent in solid tumours and provides potential opportunities for therapeutic intervention. The acidic microenvironment within a tumour can promote migration, invasi...
    Carol Ward ... Simon P Langdon
    Published: April 28, 2020 Explor Target Antitumor Ther. 2020;1:71-100
    DOI: https://doi.org/10.37349/etat.2020.00005